In 2022, 29.5 million people aged 12 or older had a past year alcohol use disorder (AUD) in the United States. Among those with AUD, only 7.6% received any type of treatment in the past year and less than 2% took a Food and Drug Administration (FDA)-approved medication for AUD (MAUD). Lack of AUD focused education and training for healthcare professionals, particularly on MAUD, is a contributing factor to the treatment gap. This in-person session at NatCon25 aims to close that gap by building skills to diagnose AUD, determine a MAUD based on the patient goals, and how to manage alcohol withdrawal syndrome. By the end of the session, participations will be able to:
Recognize how to apply non-stigmatizing language when engaging with patients with alcohol use disorder.
Describe the criteria for alcohol use disorder (AUD), the three FDA-approved medications for AUD, and how best to determine a medication regimen based on the patient’s health and goals.
Demonstrate how to assess risk for alcohol withdrawal syndrome and determine a treatment plan based on risk.
This session is hosted by the National Council for Mental Wellbeing. National Council is a PCSS-MAUD partner.